证券代码：832982 证券简称：锦波生物 公告编号：2024-084 山西锦波生物医药股份有限公司 2024 年第三次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 4.会议召集人：公司董事会 5.会议主持人：公司董事长杨霞女士 6.召开情况合法、合规、合章程性说明： 2024 年 8 月 21 日，公司第四届董事会第二次会议审议通过了《关于提请 召开公司 2024 年第三次临时股东大会的议案》。 本次股东大会的召集、召开程序符合有关法律、行政法规、部门规章、规 范性文件和本公司章程的相关规定。本次会议召开不需要相关部门的批准或履 行其他必要的程序。 （二）会议出席情况 出席和授权出席本次股东大会的股东共 12 人，持有表决权的股份总数 57,388,765 股，占公司有表决权股份总数的 64.84%。 其中通过网络投票参与本次股东大会的股东共 6 人，持有表决权的股份总数 1.会议召开时间：2024 年 9 月 9 日 2.会议召开地 ...

1、本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果及会议决议发表法律意见,并不对本次股东大 会所审议的议案、议案所涉及的数字及内容发表意见。 2、本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则(试行)》等规定及本《法律意见书》出 具日以前已经发生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚 实信用原则,进行了充分的核查验证,保证本《法律意见书》所认定的事实真实、 准确、完整,所发表的结论性意见合法、准确,不存在虚假记载、误导性陈述或 者重大遗漏,并承担相应法律责任。 3、锦波生物已向本所出具书面文件,确认其提供的所有文件原件均是真实、 准确、完整的;所有复印件均与其原件相一致;所有原件或复印件的签名及盖 G E Y U A N 格 远 律 师 事 务 所 aw Firm 关于山西锦波生物医药股份有限公司 2024年第三次临时股东大会的 法律意见书 为出具本《法律意见书》,本所声明如下: L 山西格远律师事务所 关于山西锦波生物医药股份有限公司 2024 年第三次临时股东大会的 法律意见书 致:山 ...

G E Y U A N 格 远 律 师 事 务 所 aw Firm 关于山西锦波生物医药股份有限公司 2024年第三次临时股东大会的 法律意见书 L 山西格远律师事务所 关于山西锦波生物医药股份有限公司 2024 年第三次临时股东大会的 法律意见书 致:山西锦波生物医药股份有限公司 根据《中华人民共和国证券法(2019年修订(以下简称"《证券法》"》《中 华人民共和国公司法(2023年修正)》(以下简称"《公司法》")《北京证券交易 所上市公司持续监管办法》《上市公司信息披露管理办法》等法律、法规和其他 有关规范性文件的要求,山西格远律师事务所(以下简称"本所")接受山西锦 波生物医药股份有限公司(以下简称"锦波生物"或"公司")的委托,指派律 师参加公司 2024年第三次临时股东大会(以下简称"本次股东大会"或"本次 会议")。 为出具本《法律意见书》,本所声明如下: 1、本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果及会议决议发表法律意见,并不对本次股东大 会所审议的议案、议案所涉及的数字及内容发表意见。 2、本所及经办律师依据《证券法》《律师事务所从事证 ...

证券代码：832982 证券简称：锦波生物 公告编号：2024-084 山西锦波生物医药股份有限公司 2024 年第三次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 2024 年 8 月 21 日，公司第四届董事会第二次会议审议通过了《关于提请 召开公司 2024 年第三次临时股东大会的议案》。 本次股东大会的召集、召开程序符合有关法律、行政法规、部门规章、规 范性文件和本公司章程的相关规定。本次会议召开不需要相关部门的批准或履 行其他必要的程序。 （二）会议出席情况 出席和授权出席本次股东大会的股东共 12 人，持有表决权的股份总数 57,388,765 股，占公司有表决权股份总数的 64.84%。 （一）会议召开情况 1.会议召开时间：2024 年 9 月 9 日 2.会议召开地点：山西综改示范区太原唐槐园区锦波街 18 号公司九楼会议 室 3.会议召开方式：现场投票及网络投票 4.会议召集人：公司董事会 5.会议主持人：公司董事长杨霞女士 6.召开情 ...

Investment Rating - The report maintains a "Buy" rating for the company with a market price of 173.31 CNY per share [1]. Core Insights - The company reported a Q2 revenue of 380 million CNY, reflecting a year-over-year growth of 100%, and a net profit of 208 million CNY, which is a 213% increase year-over-year, closely aligning with the previously forecasted growth range of 186% to 217% [4]. - For the first half of 2024, the company achieved a revenue of 600 million CNY, up 91% year-over-year, and a net profit of 310 million CNY, representing a 183% increase [4]. - The company continues to demonstrate strong growth despite a weak overall consumer market and high base figures in the medical aesthetics sector, indicating robust product acceptance and consumer repurchase behavior [4]. Financial Performance Summary - Revenue projections for the company are as follows: 2023A at 780 million CNY, 2024E at 1,405 million CNY, 2025E at 1,978 million CNY, and 2026E at 2,483 million CNY, with growth rates of 100% in 2023, 80% in 2024, 41% in 2025, and 26% in 2026 [1][7]. - Net profit forecasts are 300 million CNY for 2024E, 603 million CNY for 2025E, and 849 million CNY for 2026E, with corresponding growth rates of 175% in 2023, 101% in 2024, 41% in 2025, and 27% in 2026 [1][7]. - The company’s gross margin improved to 91.58%, up 2.4 percentage points year-over-year, indicating enhanced profitability [5]. Product Performance - Medical device revenue for the first half of 2024 reached 530 million CNY, a 92% increase year-over-year, while functional skincare products generated 48 million CNY, up 54% [5]. - The company has expanded its market presence, increasing the number of covered medical institutions from 2,000 to 3,000, which is expected to further broaden its consumer base [5]. Investment Recommendations - The company is expected to maintain strong growth momentum, with net profit projections of 600 million CNY for 2024, 850 million CNY for 2025, and 1,080 million CNY for 2026, corresponding to P/E ratios of 25, 18, and 14 respectively [5][7]. - The report emphasizes the potential of the company’s product pipeline, particularly in gel products, which could serve as catalysts for future growth [5].

Investment Rating - The investment rating for the company is "Buy" with a target price indicating a potential upside of over 20% within the next six months [2][9]. Core Views - The company reported strong financial performance for the first half of 2024, achieving revenue of 600 million yuan, a year-on-year increase of 90.59%, and a net profit of 310 million yuan, up 182.88% year-on-year, reaching the upper limit of its earnings forecast [1]. - The company is positioned as a leader in the recombinant collagen market, with significant growth expected in its medical aesthetics segment, particularly through its brand Wei Yi Mei [1][2]. - The company is focusing on expanding its product matrix and increasing R&D investment, which is expected to drive future growth [1]. Financial Performance Summary - For 2024H1, revenue from medical devices was 530 million yuan, a 91.84% increase year-on-year, with a gross margin of 94.43% [1]. - Revenue from functional skincare products reached 50 million yuan, a 53.94% increase year-on-year, with a gross margin of 64.76% [1]. - Revenue from raw materials was 24 million yuan, a significant increase of 180.07% year-on-year, with a gross margin of 83.03% [1]. - The company has completed foundational research on various types of recombinant human collagen and is actively conducting application research in multiple medical fields [1]. Financial Forecast - The company is projected to achieve net profits of 605 million yuan, 850 million yuan, and 1,156 million yuan for the years 2024, 2025, and 2026, respectively [1][5]. - The expected growth rates for net profit are 101.65%, 40.67%, and 35.95% for the years 2024, 2025, and 2026 [5]. - The projected P/E ratios for the years 2024, 2025, and 2026 are 25, 18, and 13, respectively [1][5].

证券代码：832982 证券简称：锦波生物 公告编号：2024-083 山西锦波生物医药股份有限公司 投资者关系活动记录表 | --- | |--------------------------------------------------------------------| | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 | | 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 | | 担个别及连带法律责任。 | 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 √其他 (电话会议) 二、 投资者关系活动情况 活动时间：2024 年 8 月 26 日 活动地点：电话会议 参会单位：中信证券、国金证券、国元证券、鹏扬基金、微明恒远投资、鑫 元基金、丹羿投资、汇安基金、国信证券、西部证券、泰康资产、摩根大通、德 邦证券、金木资本、华创证券、中邮证券、浙商证券、金鹰基金、大成基金、中 泰证券、海通证券、平安人寿、双安资产、上海证券、中银证券、国寿安保基金、 前海联合基金、第一上海证券、汇华理财、东莞证券 ...

Group 1: Company Overview and Investor Relations - The company is Shanxi Jinbo Biological Pharmaceutical Co., Ltd., with stock code 832982 and abbreviation Jinbo Bio [1] - The investor relations activity was a telephone conference held on August 26, 2024, attended by various securities firms and investment funds [2][3] Group 2: Technology and Product Development - Jinbo Bio leads in recombinant humanized collagen technology, having solved four core issues: overcoming immunogenicity, achieving a precise triple helix structure, high activity (nearly 2 times that of human type III collagen), and enabling industrial-scale production [4][5] - The company has developed a self-crosslinking gel that does not use any crosslinking agents, enhancing support and longevity [5] Group 3: Clinical Progress and Market Position - The company has submitted a registration application for its mid-face volumizing gel product to the National Medical Products Administration, highlighting its competitive advantages over existing products [5][6] - In the functional skincare segment, the company achieved revenue of 47.98 million yuan in the first half of 2024, representing a year-on-year growth of 53.94% [8] Group 4: Strategic Partnerships and Growth - In the first half of 2024, the collaboration with L'Oréal deepened, with raw materials being used in both "Paris L'Oréal" and "SkinCeuticals" brands, contributing to increased revenue and brand influence [7] - The company plans to invest up to 220 million yuan in a production workshop for injectable recombinant humanized collagen, aiming to strengthen its leading position in the injection market [9]

山西锦波生物医药股份有限公司 证券代码：832982 证券简称：锦波生物 公告编号：2024-083 投资者关系活动记录表 一、 投资者关系活动类别 □特定对象调研 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 √其他 (电话会议) 二、 投资者关系活动情况 活动时间：2024 年 8 月 26 日 活动地点：电话会议 参会单位：中信证券、国金证券、国元证券、鹏扬基金、微明恒远投资、鑫 元基金、丹羿投资、汇安基金、国信证券、西部证券、泰康资产、摩根大通、德 邦证券、金木资本、华创证券、中邮证券、浙商证券、金鹰基金、大成基金、中 泰证券、海通证券、平安人寿、双安资产、上海证券、中银证券、国寿安保基金、 前海联合基金、第一上海证券、汇华理财、东莞证券、国投瑞银基金、观合资产、 沣杨资产、中金公司、国泰君安证券、观富资产、中骏资本、华福证券、财通基 金、平安证券、崇山投资、开源证券、东方马拉松投资、民晟资产、信璞投资、 国新投资、 ...

| --- | --- | |-------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...